Antibiotic Usage and Bacterial Resistance in Psychiatric Hospitals During the COVID-19 Epidemic

Study Background and Research Question

The COVID-19 pandemic has profoundly disrupted healthcare delivery worldwide, intensifying the challenges of infection control, especially in institutions with vulnerable populations such as psychiatric hospitals. These facilities must address the dual needs of mental health care and the prevention of infectious disease outbreaks. The reference study (Jiang et al., 2025) investigates how antibacterial drugs were used and how bacterial resistance patterns evolved in a psychiatric hospital during the 2022 epidemic. The central research question is: How did the rational use of antibiotics impact bacterial resistance in this unique hospital environment during the pandemic?

Key Innovation from the Reference Study

This research stands out by integrating detailed clinical usage data with microbiological resistance surveillance, specifically within the context of a psychiatric hospital during a global epidemic. While much literature focuses on general hospitals, this study highlights psychiatric facilities' specific challenges—such as patients’ reduced self-care capabilities and increased susceptibility to infection due to antipsychotic-induced immunosuppression. The authors correlate antibiotic stewardship metrics with real-world resistance outcomes, offering actionable insights for optimizing antimicrobial strategies in similar settings.

Methods and Experimental Design Insights

The study utilized a retrospective, observational design. Data were systematically collected via the hospital information system and the National Antibacterial Drug Clinical Application Monitoring Network. Key parameters included:

• Antibiotic use rate and intensity (AUD)
• Combined medication rate
• Cumulative defined daily doses (DDDs)
• Percentage of antibiotic costs in total drug expenditures
• Rate of microbiological sample submission for antibacterial therapy
• Microbial identification and antibiotic susceptibility testing results

The data set encompassed all antibacterial drug use and bacterial culture results from the psychiatric hospital in 2022, with comparative benchmarks from both Jiangsu Province and nationwide surveillance data.

Core Findings and Why They Matter

The study’s quantitative results are notable for both their restraint in antibiotic use and for the surveillance rigor:

• The antibiotic use rate was 5.00%, and usage intensity was 3.07—both considerably lower than provincial and national averages.
• The microbiological submission rate for antibiotic therapy was 77.78%, significantly higher than external comparators, indicating strong adherence to diagnostic stewardship.
• The most commonly used antibiotics were third-generation cephalosporins, penicillins, and quinolones, with cefodizime, amoxicillin, and piperacillin–tazobactam accounting for the highest cumulative DDDs.
• Gram-negative bacteria displayed resistance primarily to penicillins, cephalosporins, and quinolones; Gram-positive bacteria were chiefly resistant to penicillins, macrolides, and quinolones.

Despite appropriate overall antibiotic use, the study observed a positive correlation between increased antimicrobial consumption and rising bacterial resistance rates within the hospital, echoing global concerns around the proliferation of multidrug-resistant organisms. This finding underscores the persistent tension between necessary infection management and the risk of resistance development, especially in psychiatric settings where patient vulnerability is compounded by environmental and immunological factors (Jiang et al., 2025).

Comparison with Existing Internal Articles

While the reference paper focuses on antibacterial stewardship and resistance, it complements the mechanistic and workflow-oriented insights available in internal literature on anti-inflammatory research tools such as gamma-linolenic acid (GLA). For example, internal resources like "Applied Workflows with Gamma-linolenic Acid (GLA) in Anti-inflammatory Research" and "Gamma-linolenic Acid: Advancing Anti-Inflammatory and Apoptosis Assays" provide actionable protocols for modulating inflammatory pathways and designing apoptosis assays in cellular or in vivo systems. These workflow articles emphasize how agents like GLA can be applied to dissect immune responses and support translational disease models, which could be relevant for studying inflammation or secondary infections in psychiatric patient populations. Although GLA is not an antibiotic, its use as a weak leukotriene B4 receptor antagonist and modulator of immune signaling may offer adjunctive insights for anti-inflammatory research aligned with infection management strategies discussed in the reference study.

Limitations and Transferability

The study’s findings are robustly supported by comprehensive, hospital-wide data and external benchmarking. However, several limitations affect generalizability:

• Data are drawn from a single psychiatric hospital, and institutional practices may not reflect those in other regions or healthcare systems.
• The retrospective design precludes causal inference; observed associations between antibiotic use and resistance cannot establish direct causality.
• Changes in the patient population or infection control policies specific to the pandemic period may limit the applicability of results to non-epidemic contexts.

Transferability to other psychiatric hospitals or broader healthcare environments should thus be approached with caution, and ongoing prospective monitoring is recommended.

Protocol Parameters

• Antibiotic stewardship data collection: Retrospectively extract usage, cost, and microbiological data for at least one calendar year using hospital information systems and standard monitoring networks.
• Sample submission rate tracking: Monitor and aim for a microbiological submission rate exceeding 75% for antibacterial therapy episodes to support rational use.
• Resistance profiling: Perform comprehensive susceptibility testing for both Gram-negative and Gram-positive isolates, focusing on commonly used antibiotics such as penicillins, cephalosporins, and quinolones.
• Comparative benchmarking: Regularly compare institutional antibiotic usage and resistance data with regional and national surveillance reports to identify trends and intervention points.

Why this cross-domain matters, maturity, and limitations

Although the primary domain of this study is antibiotic stewardship, integrating anti-inflammatory research tools—such as GLA—can be valuable when exploring host-pathogen interactions or adjunctive therapies targeting inflammatory sequelae of infection. Psychiatric patients may particularly benefit from research into immunomodulatory interventions, given their heightened vulnerability to both infection and adverse inflammatory responses. However, the literature to date does not support direct clinical application of GLA or similar agents for bacterial resistance management, and further translational research is warranted.

Research Support Resources

For laboratories aiming to reproduce or extend anti-inflammatory and immune modulation workflows highlighted in internal resources, Gamma-linolenic acid (GLA) (SKU C5518) is available from APExBIO. This compound's well-characterized properties as a weak LTB4 receptor antagonist and omega-6 polyunsaturated fatty acid have enabled its use in studies of inflammation, apoptosis, and immune signaling. Researchers can leverage GLA in both cell-based and in vivo models to investigate inflammation-relevant pathways, complementing antibacterial stewardship and resistance monitoring strategies identified in the reference study.